Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Associations Between End-of-Life Discussions, Patient Mental Health, Medical Care Near Death, and Caregiver Bereavement Adjustment
Wright, A. A. (2008) · JAMA · doi:10.1001/jama.300.14.1665 · Cited by 2,788 · cited 1×
“In the largest prospective trials of communication, doctors only ever discussed prognosis with their patients with advanced cancer in 38% of cases(179) and only had a conversation about imminent death in 37% of cases.(180)”
Background
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948
Self-citation
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Self-citation
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
Self-citation
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
Karnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,521
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
Self-citation
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V. A., Hirsh, V., Leighl, N. B., Mezger, J. M., Archer, V. R., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,501
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453
Self-citation
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W. T., Smith, T. J., Baker, S., Olak, J., Stover, D. E., Strawn, J. R., Turrisi, A. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,411
Self-citation
Anthropometric Reference Data for Children and Adults: United States, 2003-2006: (623932009-001)
McDowell, M. A., Fryar, C. D., Ogden, C. L., & Flegal, K. M. (2008) · PsycEXTRA Dataset · doi:10.1037/e623932009-001 · Cited by 1,378
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Fossella, F. V., DeVore, R. F., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L. A., Miller, V. A., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346
Relationship between cancer patients' predictions of prognosis and their treatment preferences
Weeks, J. C. (1998) · JAMA · doi:10.1001/jama.279.21.1709 · Cited by 1,319
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Kim, E. S., Hirsh, V., Mok, T. S. K., Socinski, M. A., Gervais, R., Wu, Y.-L. L. C., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,241
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Fossella, F. V., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V. A., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 938
Health Care Costs in the Last Week of Life: Associations With End-of-Life Conversations
Zhang, B., Wright, A. A., Huskamp, H. A., Nilsson, M. E., Maciejewski, M. L., Earle, C. C., Block, S. D., Maciejewski, P. K., & Prigerson, H. G. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.587 · Cited by 898
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
Scagliotti, G. V., de Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Rosa, F. D., Milanowski, J., Karnicka-Mlodkowski, H., Pešek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 875
Ethnic and Racial Differences in the Smoking-Related Risk of Lung Cancer
Haiman, C. A., Stram, D. O., Wilkens, L. R., Pike, M. C., Kolonel, L. N., Henderson, B. E., & Marchand, L. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa033250 · Cited by 780
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R. A., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M., Gralla, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9591 · Cited by 740
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
Riely, G. J., Pao, W. J., Ceppa, D. P., Li, A. R., Rizvi, N. A., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 730
Self-citation
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
Albain, K. S., Crowley, J. J., LeBlanc, M. L., & Livingston, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1618 · Cited by 729
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 696
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0232 · Cited by 690
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Ohe, Y., Ohashi, Y., Kubota, K., Tamura, T., Nakagawa, K., Negoro, S., Nishiwaki, Y., Saijo, N., Ariyoshi, Y., & Fukuoka, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl377 · Cited by 633
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612
Self-citation
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials
NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 598
Self-citation
Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis
Hagerty, R. G., Butow, P. N., Ellis, P. M., Lobb, E. A., Pendlebury, S. C., Leighl, N., Mac Leod, C., & Tattersall, M. H. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.138 · Cited by 582
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
Hirsch, F. R., Varella‐Garcia, M., McCoy, J., West, H., Xavier, A. C., Gumerlock, P. H., Bunn, P. A., Franklin, W. A., Crowley, J. J., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2823 · Cited by 574
The impact of the internet on cancer outcomes.
Eysenbach, G. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.6.356 · Cited by 573
KRAS Mutations in Non-Small Cell Lung Cancer
Riely, G. J., Marks, J., & Pao, W. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-107lc · Cited by 550
Self-citation
Detection of p53 Gene Mutations in Human Brain Tumors by Single-strand Conformation Polymorphism Analysis of Polymerase Chain Reaction Products
Mashiyama, S., Kayama, T., Katakura, R., Yoshimoto, T., Murakami, Y., Sekiya, T., & Hayashi, K. (1991) · Springer eBooks · doi:10.1007/978-4-431-68150-2_41 · Cited by 538
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509
Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial
Langer, C. J. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.3.173 · Cited by 501
Treatment of Non-small Cell Lung Cancer-Stage IIIA
Robinson, L. A., Ruckdeschel, J. C., Wagner, H., & Stevens, C. W. (2007) · CHEST Journal · doi:10.1378/chest.07-1379 · Cited by 457
Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer
Cobo, M., Isla, D., Massutí, B., Montés, A. F., Sánchez, J. M., Provencio, M., Viñolas, N., Paz-Ares, L. G., López-Vivanco, G., Muñoz, M. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7915 · Cited by 443
Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)
Lilenbaum, R., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.172 · Cited by 443
Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews
Silvestri, G. A., Pritchard, R., & Welch, H. G. (1998) · BMJ · doi:10.1136/bmj.317.7161.771 · Cited by 430
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., Chen, R., Hristova‐Kazmierski, M. K., Treat, J., Obasaju, C. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1405 · Cited by 418
Self-citation
Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.
Evans, W. K. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.08.002 · Cited by 405
Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From Cancer
Matsuyama, R. K., Reddy, S., & Smith, T. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6236 · Cited by 403
Self-citation
Amplification and Enhanced Expression of the Epidermal Growth Factor Receptor Gene in A431 Human Carcinoma Cells
Merlino, G. T., Xu, Y.-H., Ishii, S., Clark, A., Semba, K., Toyoshima, K., Yamamoto, T. S., & Pastan, I. H. (1984) · Science · doi:10.1126/science.6200934 · Cited by 401
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer
Herbst, R. S., O’Neill, V., Fehrenbacher, L., Belani, C. P., Bonomi, P., Hart, L. L., Melnyk, O. O., Ramies, D. A., Lin, M., & Sandler, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3026 · Cited by 394
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
Wacker, B., Nagrani, T., Weinberg, J., Witt, K., Clark, G. M., & Cagnoni, P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2610 · Cited by 385
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
Socinski, M. A., Schell, M. J., Peterman, A. H., BAKRI, K. M., Yates, S., Gitten, R., Unger, P., Lee, J., Lee, J.-H., Tynan, M. T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1335 · Cited by 377
Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline
Pisters, K. M. W., Evans, W. K., Azzoli, C. G., Kris, M. G., Smith, C. A., Desch, C. E., Somerfield, M. R., Brouwers, M. C., Darling, G. E., Ellis, P. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1226 · Cited by 366
Self-citation
Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.109 · Cited by 364
Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature
DʼAddario, G., Pintilie, M., Leighl, N. B., Feld, R. D., Cerny, T., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.045 · Cited by 363
Racial differences in trust and lung cancer patients' perceptions of physician communication.
Gordon, H., Street, R. L., Sharf, B. F., Kelly, P. A., & Souchek, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1955 · Cited by 362
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
Kudoh, S., Takeda, K., Nakagawa, K., Takada, M., Katakami, N., Matsui, K., Shinkai, T., Sawa, T., Goto, I., Semba, H., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1044 · Cited by 360 · cited 3×
“Two studies showed no difference in health-related QOL (HRQOL) on the basis of age,(27,67) whereas one found better HRQOL with docetaxel for elderly participants.(26)”
BackgroundResultInfluential
Racial differences in doctors' information‐giving and patients' participation
Gordon, H. S., Street, R. L., Sharf, B. F., & Souchek, J. (2006) · Cancer · doi:10.1002/cncr.22122 · Cited by 356
Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
Rosell, R., Danenberg, K. D., Alberola, V., Bepler, G., Sánchez, J. J., Camps, C., Provencio, M., Isla, D., Tarón, M., Díz, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0156 · Cited by 352
Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
Ramalingam, S. S., Dahlberg, S. E., Langer, C. J., Gray, R. J., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1144 · Cited by 348
Self-citation
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
Delbaldo, C., Michiels, S., Syz, N., Soria, J., Chevalier, T. L., & Pignon, J. (2004) · JAMA · doi:10.1001/jama.292.4.470 · Cited by 343
“Let Me See If I Have This Right …”: Words That Help Build Empathy
Coulehan, J. L., Platt, F. W., Egener, B., Frankel, R. M., Lin, C., Lown, B. A., & Salazar, W. H. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-3-200108070-00022 · Cited by 321
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K. D., Danenberg, P. V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl300 · Cited by 321
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
Brodowicz, T., Krzakowski, M. J., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N., Ciuleanu, T., Čučević, B., Gyurkovits, K., Ulsperger, E., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.006 · Cited by 320
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
Roszkowski, K., Pluzanska, A., Krzakowski, M. J., Smith, A. P., Saigí, E., Aasebø, U., Parisi, A., Tran, N. P., Olivares, R., & Bérille, J. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00094-5 · Cited by 308
Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer
Ranson, M. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.13.1074 · Cited by 305
Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer
Jackman, D. M., Yeap, B. Y., Lindeman, N. I., Fidias, P., Rabin, M. S., Temel, J. S., Skarin, A. T., Meyerson, M. M., Tisch, A. H., Borras, A. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5754 · Cited by 304
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
Rosell, R., Gatzemeier, U., Betticher, D. C., Keppler, U., Macha, H.-N., Pirker, R., Berthet, P., Breau, J. L., LIANES, P., Nicholson, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf332 · Cited by 299
The Role of Chemotherapy at the End of Life: “When Is Enough, Enough?”
Harrington, S. E., & Smith, T. J. (2008) · JAMA · doi:10.1001/jama.299.22.2667 · Cited by 280
Self-citation
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
Asahina, H., Yamazaki, K., Kinoshita, I., Sukoh, N., Harada, M., Yokouchi, H., Ishida, T., Ogura, S., Kojima, T., Okamoto, Y., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603393 · Cited by 276
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
Hirsch, F. R., Herbst, R. S., Olsen, C. C., Chansky, K., Crowley, J. J., Kelly, K. L., Franklin, W. A., Bunn, P. A., Varella‐Garcia, M., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0111 · Cited by 273
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
Hirsch, F. R., Varella‐Garcia, M., Cappuzzo, F., McCoy, J., Bemis, L., Xavier, A. C., Dziadziuszko, R., Gumerlock, P. H., Chansky, K., West, H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm003 · Cited by 270
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
Dowlati, A., Gray, R. J., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 264
Self-citation
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Rosell, R., Robinet, G., Szczęsna, A., Ramlau, R., Constenla, M., Mennecier, B., Pfeifer, W., O'Byrne, K. J., Welte, T., Kolb, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm474 · Cited by 258
Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
Gridelli, C., Gallo, C., Shepherd, F. A., Illiano, A., Piantedosi, F., Robbiati, S. F., Manzione, L., Barbera, S., Frontini, L., Veltri, E. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.099 · Cited by 247
The Effect of Race on Invasive Staging and Surgery in Non–Small-Cell Lung Cancer
Lathan, C. S., Neville, B. A., & Earle, C. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1758 · Cited by 240
The ELVIS Trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Gridelli, C. (2001) · The Oncologist · doi:10.1634/theoncologist.6-suppl_1-4 · Cited by 239
Missed Opportunities for Interval Empathy in Lung Cancer Communication
Morse, D. S., Edwardsen, E. A., & Gordon, H. S. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.17.1853 · Cited by 232
Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials
Rajeswaran, A., Trojan, A., Burnand, B., & Giannelli, M. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.012 · Cited by 220
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial
Cappuzzo, F., Ligorio, C., Janne, P. A., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Tisch, A. H., Magrini, E., Finocchiaro, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4300 · Cited by 210
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
Tibaldi, C., Giovannetti, E., Vasile, E., Mey, V., Laan, A. C., Nannizzi, S., Marsico, R. D., Antonuzzo, A., Orlandini, C., Ricciardi, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1364 · Cited by 209
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life
Spiro, S. G. (2004) · Thorax · doi:10.1136/thx.2003.020164 · Cited by 206
Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group
Sederholm, C., Hillerdal, G., Lamberg, K., Kölbeck, K. G., Dufmats, M., Westberg, R., & Gawande, S. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2781 · Cited by 206
Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
Langer, C. J., O'Byrne, K. J., Socinski, M. A., Mikhailov, S. M., Leśniewski-Kmak, K., Šmakal, M., Ciuleanu, T., Orlov, S., Dediu, M., Heigener, D. F., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181753b4b · Cited by 203
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
Tamura, K., Okamoto, I., Kashii, T., Negoro, S., Hirashima, T., Kudoh, S., Ichinose, Y., Ebi, N., Shibata, K., Nishimura, T., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604249 · Cited by 201
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
Massarelli, E., André, F., Liu, D. D., Lee, J. J., Wolf, M., Fandi, A., Ochs, J., Chevalier, T. L., Fossella, F. V., & Herbst, R. S. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00308-2 · Cited by 200
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
Burdett, S., Stephens, R. J., Stewart, L. A., Tierney, J. F., Auperin, A., Chevalier, T. L., Pechoux, C. L., Pignon, J., Arriagada, R., Higgins, J. P., et al. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 196
Self-citation
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D. H., Alam, Y., Kreisman, H., Graze, P. R., Maher, J. F., Ross, H. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0856 · Cited by 195
Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial
Alberola, V., Camps, C., Provencio, M., Isla, D., Rosell, R., Vadell, C., Bover, I., Ruiz‐Casado, A., Azagra, P., Jiménez, U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.038 · Cited by 193
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer
Rosell, R., Scagliotti, G. V., Danenberg, K. D., Lord, R. V., Bepler, G., Novello, S., Cooc, J., Crinò, L., Sánchez, J. J., Tarón, M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206419 · Cited by 188
Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
D’Addario, G., & Felip, E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp132 · Cited by 187
Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China
Wu, Y.-L. L. C., Zhong, W., Li, L.-Y., Zhang, X.-T., Zhang, L., Zhou, C.-C., Liu, W., Jiang, B., Mu, X.-L., Lin, J.-Y., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268677.87496.4c · Cited by 186
Women's Perceptions of Breast Cancer Risk
Woloshin, S., Schwartz, L. M., Black, W. C., & Welch, H. G. (1999) · Medical Decision Making · doi:10.1177/0272989x9901900301 · Cited by 181
Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer
Park, J. O., Kim, S., Ahn, J. S., Suh, C., Lee, J. S., Jang, J. S., Cho, E. K., Yang, S. H., Choi, J., Heo, D. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8134 · Cited by 180
Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel
Schuette, W., Nagel, S., Blankenburg, T., Lautenschlaeger, C., Hans, K., Schmidt, E.-W., Dittrich, I., Schweisfurth, H., von Weikersthal, L. F., Raghavachar, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3739 · Cited by 179
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer
Simon, G. R., Sharma, A., Li, X., Hazelton, T. R., Walsh, F. W., Williams, C. C., Chiappori, A., Haura, E. B., Tanvetyanon, T., Antonia, S. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2099 · Cited by 178
Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2
Lilenbaum, R., Axelrod, R. S., Thomas, S. P., Dowlati, A., Seigel, L., Albert, D., Witt, K., & Botkin, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2720 · Cited by 176
Turning Gray: The Natural History of Lung Cancer Over Time
Detterbeck, F. C., & Gibson, C. J. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c9230 · Cited by 174
Impact of Referral Patterns on the Use of Chemotherapy for Lung Cancer
Earle, C. C., Neumann, P. J., Gelber, R. D., Weinstein, M. C., & Weeks, J. C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.142 · Cited by 174
FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
Pirker, R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Park, K., Gatzemeier, U., Bajeta, E., Emig, M., & Pereira, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3 · Cited by 172
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
Paz-Ares, L. G., Ross, H. J., O'Brien, M. E. R., Riviere, A., Gatzemeier, U., von Pawel, J., Kaukel, E., Freitag, L., Digel, W., Bischoff, H. G., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604372 · Cited by 171
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
Shih, J., Gow, C., Yu, C., Yang, C., Chang, Y., Tsai, M., Hsu, Y., Chen, K., Su, W., & Yang, P. (2005) · International Journal of Cancer · doi:10.1002/ijc.21458 · Cited by 170
Abandonment at the End of Life From Patient, Caregiver, Nurse, and Physician Perspectives
Back, A. L., Young, J. P., McCown, E., Engelberg, R. A., Vig, E. K., Reinke, L. F., Wenrich, M. D., McGrath, B. B., & Curtis, J. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.583 · Cited by 169
Treatment of Non-small Cell Lung Cancer, Stage IV
Socinski, M. A., Crowell, R. E., Hensing, T., Langer, C. J., Lilenbaum, R., Sandler, A. B., & Morris, D. (2007) · CHEST Journal · doi:10.1378/chest.07-1381 · Cited by 169
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
Sutani, A., Nagai, Y., Udagawa, K., Uchida, Y., Koyama, N., Murayama, Y., Tanaka, T., Miyazawa, H., Nagata, M., Kanazawa, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603466 · Cited by 167
Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer
Yoshida, K., Yatabe, Y., Park, J. Y., Shimizu, J., Horio, Y., Matsuo, K., Kosaka, T., Mitsudomi, T., & Hida, T. (2007) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30013-7 · Cited by 165
Necessary Collusion: Prognostic Communication With Advanced Cancer Patients
Helft, P. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.003 · Cited by 164
Do doctors know when their patients don't?
Quirt, C. F., Mackillop, W. J., Ginsburg, A. D., Sheldon, L., Brundage, M., Dixon, P., & Ginsburg, L. (1997) · Lung Cancer · doi:10.1016/s0169-5002(97)00048-2 · Cited by 162
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
on behalf of the DISTAL (Docetaxel In Second-line Treatment of Advanced Lung cancer) Investigators, Gridelli, C., Gallo, C., Maïo, M. D., Barletta, E., Illiano, A., Maione, P., Salvagni, S., Piantedosi, F. V., Palazzolo, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602241 · Cited by 162
Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial
Georgoulias, V., Ardavanis, A. S., Tsiafaki, X., Agelidou, A., Mixalopoulou, P., Anagnostopoulou, O., Ziotopoulos, P., Toubis, M., Syrigos, K., Samaras, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.016 · Cited by 160
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial
Zatloukal, P., Petruzelka, L. B., Zemanová, M., Kolek, V., Skřičková, J., Pešek, M., Fojtů, H., Grygárková, I., Sixtová, D., Roubec, J., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00233-2 · Cited by 159
Discussing Prognosis: “How Much Do You Want to Know?” Talking to Patients Who Are Prepared for Explicit Information
Back, A. L., & Arnold, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.007 · Cited by 159
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
for the Norwegian Lung Cancer Study Group, von Plessen, C., Bergman, B., Andresen, O., Bremnes, R. M., Sundstrøm, S. H., Gilleryd, M., Stephens, R. J., Vilsvik, J., Aasebø, U., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603383 · Cited by 158
Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Clark, G. M., Zborowski, D. M., Santabarbara, P., Ding, K., Whitehead, M., Seymour, L., & Shepherd, F. A. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.n.022 · Cited by 158
Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group
Rudd, R., Gower, N. H., Spiro, S. G., Eisen, T. G., Harper, P., Littler, J. A. H., Hatton, M. Q. F., Johnson, P., Martin, W. M. C., Rankin, E. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.037 · Cited by 158
Population Variations in the Initial Treatment of Non–Small-Cell Lung Cancer
Potosky, A. L., Saxman, S. B., Wallace, R. B., & Lynch, C. F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.051 · Cited by 156
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
Čufer, T., Vrdoljak, E., Gaafar, R. M., Erensoy, I., & Pemberton, K. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000203381.99490.ab · Cited by 151
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
for the CPT-11 Lung Cancer Study Group West, Negoro, S., Masuda, N., Takada, Y., Sugiura, T., Kudoh, S., Katakami, N., Ariyoshi, Y., Ohashi, Y., Niitani, H., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600725 · Cited by 151
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
Gandara, D. R., Crowley, J. J., Livingston, R. B., Perez, E. A., Taylor, C. W., Weiss, G. R., Neefe, J. R., Hutchins, L. F., Roach, R. W., & Grunberg, S. M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.5.873 · Cited by 150
Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Weiss, G. J., Langer, C. J., Rosell, R., Hanna, N. H., Shepherd, F. A., Einhorn, L. H., Nguyen, B. T., Paul, S., McAndrews, P., Bunn, P. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7835 · Cited by 149
Patient–oncologist communication in advanced cancer: predictors of patient perception of prognosis
Robinson, T. M., Alexander, S. C., Hays, M., Jeffreys, A. S., Olsen, M. K., Rodriguez, K. L., Pollak, K. I., Abernethy, A. P., Arnold, R. M., & Tulsky, J. A. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-007-0372-2 · Cited by 148
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
van Zandwijk, N., Mathy, A., Boerrigter, L., Ruijter, H. J., Tielen, I. H. G., de Jong, D., Baas, P., Burgers, S. A., & Nederlof, P. M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl323 · Cited by 147
Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer
Belani, C. P., Lee, J. S., Socinski, M. A., Robert, F., Waterhouse, D. M., Rowland, K. M., Ansari, R., Lilenbaum, R., & Natale, R. B. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi216 · Cited by 145
Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first‐line treatment of advanced nonsmall cell lung carcinoma (TAX 326)
Belani, C. P., & Fossella, F. V. (2005) · Cancer · doi:10.1002/cncr.21495 · Cited by 144
Lung Cancer in the Elderly
Gridelli, C., Langer, C. J., Maione, P., Rossi, A., & Schild, S. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3085 · Cited by 142
Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
Belani, C. P., Ramalingam, S. S., Perry, M. C., LaRocca, R. V., Rinaldi, D. A., Gable, P. S., & Tester, W. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1912 · Cited by 142
The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are
Koedoot, C. G., Oort, F. J., de Haan, R. J., Bakker, P. J. M., de Graeff, A., & de Haes, J. C. J. M. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.10.008 · Cited by 139
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel
Hensing, T. A., Peterman, A. H., Schell, M. J., Lee, J., & Socinski, M. A. (2003) · Cancer · doi:10.1002/cncr.11548 · Cited by 135
Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non—Small-Cell Lung Cancer: A Randomized, Multicenter Phase III Trial
Georgoulias, V., Ardavanis, A. S., Agelidou, A., Agelidou, M., Chandrinos, V., Tsaroucha, E., Toumbis, M., Kouroussis, C., Syrigos, K., Polyzos, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.004 · Cited by 134
Patient Use of the Internet for Information in a Lung Cancer Clinic*
Peterson, M. W., & Fretz, P. C. (2003) · CHEST Journal · doi:10.1378/chest.123.2.452 · Cited by 134
Communication and Racial Inequities in Health Care
Kreps, G. L. (2005) · American Behavioral Scientist · doi:10.1177/0002764205283800 · Cited by 131
Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin
Pujol, J.-L., Breton, J.-L., Gervais, R., Rebattu, P., Depierre, A., Morère, J., Milleron, B. J., Debieuvre, D., Castera, D., Souquet, P. J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi126 · Cited by 129
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial
Camps, C., Massutí, B., Jiménez, A., Maestu, I., Gómez, R. G., Isla, D., González, J., Almenar, D., Blasco, A., Rosell, R., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj115 · Cited by 129
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
Sunaga, N., Tomizawa, Y., Yanagitani, N., Iijima, H., Kaira, K., Shimizu, K., Tanaka, S., Suga, T., Hisada, T., Ishizuka, T., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.01.025 · Cited by 127
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials
Pujol, J.-L., Barlési, F., & Daurès, J. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.11.001 · Cited by 124
Management of Lung Cancer in Older Adults
Hurria, A., & Kris, M. G. (2003) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.6.325 · Cited by 111
Companion participation in cancer consultations
Street, R. L., & Gordon, H. S. (2007) · Psycho-Oncology · doi:10.1002/pon.1225 · Cited by 108
Outcomes Among African-American/Non-African-American Patients With Advanced Non-Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B
Blackstock, A. W., Herndon, J. E., Paskett, E. D., Perry, M., Graziano, S. L., Muscato, J. J., Kosty, M. P., Akerley, W., Holland, J. C., Fleishman, S. B., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.284 · Cited by 108
Physician-Identified Factors Affecting Patient Participation in Reaching Treatment Decisions
Shepherd, H. L., Tattersall, M. H. N., & Butow, P. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5566 · Cited by 104
Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival
Dudek, A. Z., & Mahaseth, H. (2005) · Cancer Investigation · doi:10.1081/cnv-200055949 · Cited by 99
Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
Ciuleanu, T., Brodowicz, T., Belani, C. P., Kim, J., Krzakowski, M. J., Laack, E., Wu, Y.-L. L. C., Peterson, P. M., Adachi, S., & Zielinski, C. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8011 · Cited by 98
A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer
Jiang, J., Liang, X., Zhou, X., Huang, R., & Chu, Z. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.03.014 · Cited by 98
A multi-institutional study of Internet utilization by radiation oncology patients
Metz, J. M., Devine, P., DeNittis, A. S., Jones, H., Hampshire, M. K., Goldwein, J. L., & Whittington, R. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00407-3 · Cited by 98
Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials
Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh476 · Cited by 97
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
Zhang, X.-T., Li, L.-Y., Mu, X. L., Cui, Q.-C., Chang, X.-Y., Song, W., Wang, S., Wang, M., Zhong, W., & Zhang, L. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi340 · Cited by 96
A decision aid to assist in adjuvant therapy choices for breast cancer
Siminoff, L. A., Gordon, N. H., Silverman, P., Budd, T. G., & Ravdin, P. M. (2006) · Psycho-Oncology · doi:10.1002/pon.1040 · Cited by 93
Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group
Laack, E., Dickgreber, N., Müller, T. R., Knuth, A. K., Benk, J., Lorenz, C., Gieseler, F., Dürk, H., Engel-Riedel, W., Dalhoff, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.576 · Cited by 90
EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Cappuzzo, F., Ligorio, C., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Magrini, E., Finocchiaro, G., Bartolini, S., Cancellieri, A., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268676.79872.9b · Cited by 89
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline
Noble, J., Ellis, P. M., MacKay, J., & Evans, W. K. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31641-5 · Cited by 87
Performance status assessment among oncology patients: a review.
Orr, S. T., & Aisner, J. (1986) · PubMed · Cited by 85
B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)
Lynch, T. J., Patel, T., Dreisbach, L. P., McCleod, M., Heim, W. J., Robert, H., Eugene, P., Pautret, V., Weber, M. R., & Woytowitz, D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283155.03863.e7 · Cited by 84
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
for the Norwegian Lung Cancer Study Group, Helbekkmo, N., Sundstrøm, S. H., Aasebø, U., Brunsvig, P. F., von Plessen, C., Hjelde, H. H., Garpestad, O. K., Bailey, A., & Bremnes, R. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603869 · Cited by 75
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
Cullen, M. H., Zatloukal, P., Sörenson, S., Novello, S., Fischer, J. R., Joy, A. A., Zereu, M., Peterson, P. M., Visseren‐Grul, C., & Iscoe, N. A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm592 · Cited by 73
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer
Hainsworth, J. D., Spigel, D. R., Farley, C. P., Shipley, D. L., Bearden, J. D., Gandhi, J. G., Houston, G. A., & Greco, F. A. (2007) · Cancer · doi:10.1002/cncr.23019 · Cited by 69
Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Gridelli, C., Ardizzoni, A., Ciardiello, F., Hanna, N. H., Heymach, J. V., Perrone, F., Rosell, R., Shepherd, F. A., Thatcher, N., Vansteenkiste, J., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168c815 · Cited by 69
EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer
Kimura, H., Kasahara, K., Shibata, K., Sone, T., Yoshimoto, A., Kita, T., Ichikawa, Y., Waseda, Y., Watanabe, K., Shiarasaki, H., et al. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31577-x · Cited by 68
Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature
Grossi, F., Aita, M., Follador, A., Defferrari, C., Brianti, A., Sinaccio, G., & Belvedere, O. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-451 · Cited by 68
Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
Hotta, K., Kiura, K., Toyooka, S., Takigawa, N., Soh, J., Fujiwara, Y., Tabata, M., Date, H., & Tanimoto, M. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318074bc0d · Cited by 67
Telling the Truth About Terminal Cancer
Smith, T. J. (1998) · JAMA · doi:10.1001/jama.279.21.1746 · Cited by 67
Self-citation
Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial
Paccagnella, A., Favaretto, A. G., Oniga, F., Barbieri, F., Ceresoli, G. L., Torri, V., Villa, E., Verusio, C., Cetto, G., Santo, A., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00280-0 · Cited by 66
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer
Sone, T., Kasahara, K., Kimura, H., Nishio, K., Mizuguchi, M., Nakatsumi, Y., Shibata, K., Waseda, Y., Fujimura, M., & Nakao, S. (2007) · Cancer · doi:10.1002/cncr.22593 · Cited by 64
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
Booton, R., Lorigan, P. C., Anderson, H., Baka, S., Ashcroft, L., Nicolson, M. C., O'Brien, M., Dunlop, D. J., O'Byrne, K. J., Laurence, V., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl078 · Cited by 64
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
Wachters, F. M., van Putten, J. W. G., Kramer, H., Erjavec, Z., Eppinga, P., Strijbos, J. H., de Leede, G. P. J., Boezen, H. M., de Vries, E. G. E., & Groen, H. J. M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601283 · Cited by 61
Front-line paclitaxel–vinorelbine versus paclitaxel–carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial
Stathopoulos, G. P., Veslemes, M., Georgatou, N., Antoniou, D., Giamboudakis, P., Katis, K., Tsavdaridis, D., Rigatos, S. K., Dimitroulis, J., Bastani, S., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh260 · Cited by 60
Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese
Uramoto, H., Sugio, K., Oyama, T., Ono, K., Sugaya, M., Yoshimatsu, T., Hanagiri, T., Morita, M., & Yasumoto, K. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.08.006 · Cited by 59
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer
Dudek, A. Z., Leśniewski-Kmak, K., Koopmeiners, J. S., & Keshtgarpour, M. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.09.002 · Cited by 59
Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer
Hirsch, F. R., Varella‐Garcia, M., Dziadziuszko, R., Xiao, Y., Gajapathy, S., Skokan, M. C., Lin, M., O’Neill, V., & Bunn, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0539 · Cited by 59
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB–IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale
Gebbia, V. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00444-0 · Cited by 59
American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges
Somerfield, M. R., Einhaus, K., Hagerty, K. L., Brouwers, M. C., Seidenfeld, J., & Lyman, G. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7139 · Cited by 58
Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life
Belani, C. P., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V. A., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P. M., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.05.003 · Cited by 56
Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer
Tan, E. H., Szczęsna, A., Krzakowski, M. J., Macha, H.-N., Gatzemeier, U., Mattson, K. V., Wernli, M., Reiterer, P., Hui, R., von Pawel, J., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.03.029 · Cited by 55
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
Han, S., Jeon, Y. K., Lee, K.-H., Keam, B., Hwang, P. G., Oh, D., Lee, S., Kim, D., Im, S., Chung, D. H., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328011abc0 · Cited by 54
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
Yang, C., Shih, J., Chen, K., Yu, C., Yang, T., Lin, C., Su, W., Gow, C., Hsu, C., Chang, G., et al. (2006) · Cancer · doi:10.1002/cncr.22220 · Cited by 54
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
Kosmidis, P., Kalofonos, H. P., Christodoulou, C., Syrigos, K. N., Makatsoris, T., Skarlos, D.-V., Bakogiannis, C., Nicolaides, C., Bafaloukos, D. I., Bamias, A., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm430 · Cited by 52
Second-line treatment for advanced non-small cell lung cancer: A systematic review
Barlési, F., Jacot, W., Astoul, P. J., & Pujol, J.-L. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.08.017 · Cited by 51
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine
Vansteenkiste, J., Vandebroek, J., Nackaerts, K. L., Dooms, C., Galdermans, D., Bosquée, L., Delobbe, A., Deschepper, K., Kerckhoven, W. V., Vandeurzen, K., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00515-9 · Cited by 51
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
Satouchi, M., Negoro, S., Funada, Y., Urata, Y., Shimada, T., Yoshimura, S., Kotani, Y., Sakuma, T., Watanabe, H., Adachi, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603710 · Cited by 47
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)
Comella, P., Filippelli, G., Cataldis, G. D., Massidda, B., Frasci, G., Maiorino, L., Putzu, C., Mancarella, S., PALMERI, S., Cioffi, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl396 · Cited by 46
Multicenter Randomized Trial for Stage IIIB/IV Non–Small-Cell Lung Cancer Using Every-3-Week Versus Weekly Paclitaxel/Carboplatin
Schuette, W., Blankenburg, T., Guschall, W.-R., Dittrich, I., Schneider, M., Schweisfurth, H., Chemaissani, A., Schumann, C., Dickgreber, N., Appel, T., et al. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.n.016 · Cited by 46
Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial
Zatloukal, P., Petruzelka, L. B., Zemanová, M., Kolek, V., Skřičková, J., Pešek, M., Sixtová, D., Roubec, M., Havel, L., & Průša, P. (2003) · Lung Cancer · Cited by 46
Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer
Gregorc, V., Ceresoli, G. L., Floriani, I., Spreafico, A., Bencardino, K. B., Ludovini, V., Pistola, L., Mihaylova, Z., Tofanetti, F. R., Ferraldeschi, M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0770 · Cited by 41
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
Pugh, T. J., Bebb, G. D., Barclay, L., Sutcliffe, M., Fee, J., Salski, C., O'Connor, R. N., Ho, C., Murray, N., Melosky, B. L., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-128 · Cited by 40
Self-citation
Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines.
Ettinger, D. S., & Johnson, B. E. (2005) · PubMed · Cited by 40
Changes in Circulating VEGF Levels in Relation to Clinical Response during Chemotherapy for Metastatic Cancer
Lissoni, P., Rovelli, F., Malugani, F., Brivio, F., Fumagalli, L. A. M., & Gardani, G. (2003) · The International Journal of Biological Markers · doi:10.1177/172460080301800209 · Cited by 40

Flagged first, then by citations

2 of the 218 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834
Self-citation
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,575

See all 915

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks